by Seq2Study

Chai-2

Chai Discovery's zero-shot antibody and miniprotein design model - access by partnership only.

Chai Discovery

What it does

Designs de novo antibodies, nanobodies and miniproteins against a target epitope, reported to need only ~20 designs per target. Input (as described by the vendor): a target antigen and epitope; output: scFv/VHH/miniprotein designs. There is no public code, no downloadable weights and no self-serve API.

Commercial use

Unverified

Licence as writtenunverified (no public licence; access granted case-by-case under the vendor's Responsible Deployment policy)

No licence text exists to read. The announcement says access is being opened to 'a number of academic and industry partners' via an early-access sign-up and granted under a Responsible Deployment policy. Terms for a commercial partner are not published, so rights are unverified. Listed here because it is widely cited and people ask - not because it is usable off the shelf.

Proof — pages read on 15 Oct 2026
  1. chaidiscovery.com/news/introducing-chai-2

We could not find a published statement that settles it (often: the model weights carry no licence). Treat as unknown.

Is commercial use free of charge?

Cost unverified

No price is published. Access is by application, and nothing in the announcement states whether partners pay, grant rights, or share results.

Proof — pages read on 15 Oct 2026
  1. chaidiscovery.com/news/introducing-chai-2

Price and rights are separate: this panel is about money, the panel above is about permission.

When to use it

Only relevant if you want to approach Chai as a partner. For in-house work today, the open antibody designers (RFantibody, Germinal, IgGM, mBER) are what you can actually run.

Facts

Maker
Chai Discovery
Cost for commercial use
Cost unverified
Open weights
No
Licence
unverified (no public licence; access granted case-by-case under the vendor's Responsible Deployment policy)
Last verified

Other antibody-specific design tools